Back to top

Dianthus (DNTH) Launches Phase 3 Trial for Claseprubart in Myasthenia Gravis

Dianthus (DNTH) Launches Phase 3 Trial for Claseprubart in Myasthenia Gravis

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Dianthus Therapeutics, Inc. (DNTH)